Autoimmune Diseases / 2011 / Article / Fig 1

Clinical Study

Matrix Metalloproteinase-3 in Myasthenia Gravis Compared to Other Neurological Disorders and Healthy Controls

Figure 1

Scatter plot of the MMP-3 concentrations in patients with neurological disorders and healthy controls. The 2 SD cut-off at 48 ng/mL is indicated.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.